LA
VRTX icon

LBP AM’s Vertex Pharmaceuticals VRTX Stock Holding History

LBP AM’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.2M Buy
98,975
+31,778
+47% +$14.8M 0.6% 31
2025
Q4 		$30.5M Buy
67,197
+22,918
+52% +$9.88M 0.35% 56
2025
Q3 		$17.3M Buy
44,279
+4,938
+13% +$2.06M 0.21% 93
2025
Q2 		$17.5M Sell
39,341
-14,200
-27% -$6.54M 0.25% 82
2025
Q1 		$26M Sell
53,541
-5,818
-10% -$2.71M 0.4% 55
2024
Q4 		$23.9M Buy
59,359
+54,646
+1,159% +$25.3M 0.32% 66
2024
Q3 		$2.19M Buy
4,713
+1,497
+47% +$719K 0.03% 247
2024
Q2 		$1.51M Buy
3,216
+1,470
+84% +$638K 0.06% 185
2024
Q1 		$730K Sell
1,746
-10,994
-86% -$4.65M 0.03% 288
2023
Q4 		$5.18M Sell
12,740
-578
-4% -$214K 0.11% 171
2023
Q3 		$4.63M Buy
13,318
+9,923
+292% +$3.47M 0.1% 194
2023
Q2 		$1.19M Sell
3,395
-9,848
-74% -$3.32M 0.03% 315
2023
Q1 		$4.17M Sell
13,243
-827
-6% -$248K 0.11% 182
2022
Q4 		$4.06M Buy
+14,070
New +$4.29M 0.12% 181

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

LBP AM's VRTX Position: Q1 2026 in Review

LBP AM increased its Vertex Pharmaceuticals (VRTX) stake by 47% in Q1 2026, buying an estimated $14.8M and bringing the position to 98,975 shares worth $44.2M. The position accounts for 0.6% of the portfolio, ranked #31.

LBP AM first reported a position in VRTX in Q4 2022 and has held it in 14 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • LBP AM held 98,975 shares of Vertex Pharmaceuticals worth $44.2M as of Q1 2026.
  • LBP AM bought 31,778 Vertex Pharmaceuticals shares in Q1 2026, an estimated $14.8M.
  • Vertex Pharmaceuticals made up 0.6% of LBP AM's portfolio in Q1 2026, its #31 holding.
  • LBP AM first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on LBP AM's 13F filing for Q1 2026, filed 27 Apr 2026.